Understanding how malaria parasites in Bangladesh resist artemisinin treatment
Deciphering P. falciparum artemisinin resistance in Bangladesh: a genotypic-phenotypic evaluation of Kelch13 dependent and independent determinants
This study is looking into why some malaria parasites don't respond to artemisinin treatment, and it's for people in the Chittagong Hill Tracts of Bangladesh who may be asked to help by providing samples so researchers can better understand how to improve malaria care.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Notre Dame NIH-funded |
| Lab location | 1 site (Notre Dame, United States) |
| Project ID | NIH-11099825 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind artemisinin resistance in malaria parasites, particularly focusing on the genetic and phenotypic factors that contribute to this resistance. By analyzing samples from the Chittagong Hill Tracts in Bangladesh, the study aims to identify mutations in the K13 gene and other potential determinants of resistance. The approach includes both clinical assessments and laboratory assays to evaluate the effectiveness of current treatments. Patients may be involved in providing samples for genetic analysis and monitoring treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with malaria in Bangladesh, particularly those who have received artemisinin-based treatments.
Not a fit: Patients who are not diagnosed with malaria or those who have not received artemisinin treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for detecting and managing artemisinin resistance, ultimately enhancing malaria treatment effectiveness.
How similar studies have performed: Previous research has shown success in identifying drug resistance mechanisms in malaria, indicating that this approach has potential for meaningful insights.
Where this research is happening
Notre Dame, United States
- University of Notre Dame — Notre Dame, United States (Active)
Researchers
- Principal investigator: Mukherjee, Angana — University of Notre Dame
- Study coordinator: Mukherjee, Angana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.